ClinicalTrials.gg
RecruitingNCT07765173ReGAINUpdated Aug 14, 2026

Muscle Function Following Anterior Cruciate Ligament Reconstruction: Impaired Power Output in Physically Active Individuals

An interventional study of assessment in ACL Surgery, sponsored by Centre Hospitalier Metropole Savoie. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Centre Hospitalier Metropole Savoie · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to to determine the extent of the association between objective changes in the muscle function of the knee extensors (strength and power) and the function reported by the patient following ACL reconstruction surgery. The main questions it aims to answer is:

- Pre- and post-operative (6 months) changes in maximum knee extensor strength following ACL reconstruction, correlated with the IKDC-SKF score.

Read the detailed description

Before surgery :

  • The patient will undergo a series of assessment tests, including:
  • An assessment of the force-velocity and power-velocity relationships for each leg during a cycling task
  • An assessment of unilateral force-velocity and power-velocity relationships during a knee extension task
  • An assessment of maximum strength and explosive strength in isometric (static) mode of the knee extensors.
  • A questionnaire-based assessment of IKDC-SKF scores. Evaluations will be repeated at 3 and 6 month after surgery ; Patients will be monitored for up to 24 months following their surgery
02

Conditions studied

  • ACL Surgery

Keywords

  • assessment
  • recovery
  • cruciate ligament
  • surgery
03

In context

Lead sponsor

Centre Hospitalier Metropole Savoie is the lead sponsor of 22 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients requiring isolated or complex ACL reconstruction (combined with a meniscal injury)
  • Patients who are physically active (Tegner score ≥ 4) and wish to resume such activity.
  • Patients with no history of surgery on the ipsilateral knee (i.e., native knee).
  • Patients able to comply with the study procedures
  • Patients who have given their free and informed written consent, having been informed of the purpose of the study, its procedure and its risks.
  • Be affiliated to a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Patient with comprehension difficulties
  • Recurrent rupture of the ipsilateral ACL
  • Multi-ligament injuries (i.e., injury to the medial collateral ligament, lateral collateral ligament or posterior cruciate ligament)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    evaluated group

    assessment of knee function before and after cruciate ligament surgery

    Other: assessment

Interventions

  • Otherassessment

    * Assessment of force-velocity and power-velocity relationships in each leg during a cycling task * Assessment of unilateral force-velocity and power-velocity relationships during a knee extension task * Assessment of maximum force and explosive force in isometric (static) conditions of the knee extensors. * Measurement of scores using questionnaires (IKDC-SKF).

06

What researchers measure

Primary outcomes

  1. Correlation of maximum knee extension strength to IKDC-SKF scores

    Relationship (r coefficient) between 0-6 month delta of maximum knee extension strength measurements and International Knee Documentation Commitee-SKF scores (100: no limitation)

    Time frame: 6 month

Secondary outcomes

  1. Peri-operatory trajectory of maximal dynamic force

    Trajectory of evolution of F0 (maximal dynamic force) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).

    Time frame: 0, 3 and 6 month

  2. Peri-operatory trajectory of maximal contraction velocity

    Trajectory of evolution of V0 (maximal contraction velocity) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).

    Time frame: 0, 3 and 6 month

  3. Peri-operatory trajectory of rate of force development

    Trajectory of evolution of rate of force development between baseline, 3 and 6 months, compared between legs (linear mixed effect model).

    Time frame: 0, 3 and 6 month

  4. Peri-operatory trajectory of maximal isometric force

    Trajectory of evolution of maximal isometric force (Fmax) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).

    Time frame: 0, 3 and 6 month

  5. Peri-operatory trajectory of maximal dynamic force during cycling

    Trajectory of evolution of maximal dynamic force (F0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).

    Time frame: 0, 3 and 6 month

  6. Peri-operatory trajectory of maximal contraction velocity during cycling

    Trajectory of evolution of maximal contraction velocity (V0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).

    Time frame: 0, 3 and 6 month

  7. Determinants of fonctional prognosis

    Multivariate analysis including the IKDC-SKF score at 24 months as dependant variable and, as predictors : 1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg. 2. the severity of the lesion (presence of associated lesions) 3. the presence of a pre-operatory rehabilitation.

    Time frame: 0, 3 and 24 month

  8. Determinants of fonctional prognosis

    Multivariate analysis including the recurrence of ACL lesion at 24 months (0/1) as dependant variable and, as predictors : 1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg. 2. the severity of the lesion (presence of associated lesions) 3. the presence of a pre-operatory rehabilitation.

    Time frame: 0, 3 and 24 month

  9. Determinants of fonctional prognosis

    Multivariate analysis including resuming physical activity at the pre-injury level at 24 months (0/1) as dependant variable and, as predictors : 1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg. 2. the severity of the lesion (presence of associated lesions) 3. the presence of a pre-operatory rehabilitation.

    Time frame: 0, 3 and 24 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2030, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Aug 14, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Jun 8, 2030
CompletionEst.
Jun 8, 2030
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07765173
Lead sponsor
Centre Hospitalier Metropole Savoie
Collaborators
Université Savoie Mont Blanc
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Jun 8, 2026
Primary completion
Jun 8, 2030 (estimated)
Completion
Jun 8, 2030 (estimated)
Last update
Aug 14, 2026

Study contacts

leo blervaque
Contact
leo.blervaque@ch-metropole-savoie.fr
04.79.96.58.13

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion